Findings

What do systematic reviews say?

4,751 questions · 12,775 findings · 807 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,413 · 26.7%GRADE not reported 709 · 5.5%Very low 3,483 · 27.3%Low 3,165 · 24.8%Moderate 1,628 · 12.7%High 377 · 3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

One oral healthcare intervention vs another oral healthcare intervention

Stroke survivor and providers' knowledge and attitudes to oral health care · people with stroke

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving oral health in people after stroke 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral care interventions (nurse-assisted toothbrushing, oral and pharyngeal cavity rinse, decontamination with antibiotics or antiseptics) vs placebo

Plaque · people with stroke

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving oral health in people after stroke 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral care interventions (nurse-assisted toothbrushing, oral and pharyngeal cavity rinse, decontamination with antibiotics or antiseptics) vs placebo

Denture plaque · people with stroke

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving oral health in people after stroke 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PUFA vs monounsaturated fatty acid (MUFA)

Relapse · people with multiple sclerosis

It is very uncertain whether polyunsaturated fatty acid (PUFA) changes relapse(assessed as number of participants experiencing relapse) compared with monounsaturated fatty acid (MUFA) (very low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 1.02 [0.88, 1.2]
3 studies · 217 participants
Very low

Omega‐3 vs omega‐6

SAEs · people with multiple sclerosis

Omega‐3 showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with omega‐6 (low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 1.12 [0.38, 3.31]
4 studies · 230 participants
Low

Antioxidants vs placebo

Relapse · people with multiple sclerosis

Antioxidant showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with placebo (low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 0.98 [0.59, 1.64]
4 studies · 345 participants
Low

Antioxidants vs placebo

Change in validated disability scale ( · people with multiple sclerosis

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 490 participants
Very low

Antioxidants vs placebo

Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis

Antioxidant showed no clear difference in global impression of deterioration (investigator defined global… compared with placebo (low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 0.99 [0.5, 1.93]
2 studies · 190 participants
Low

Antioxidants vs placebo

Number of participants with gadolinium‐enhancing T1 lesions on MRI · people with multiple sclerosis

It is very uncertain whether antioxidant changes MRI activity(assessed as number of participants with… compared with placebo (very low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 0.67 [0.09, 4.88]
2 studies · 131 participants
Very low

Antioxidants vs placebo

SAEs · people with multiple sclerosis

Antioxidant showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with placebo (low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 0.72 [0.17, 3.08]
3 studies · 222 participants
Low

PUFA vs monounsaturated fatty acid (MUFA)

Change in validated disability scale ( · people with multiple sclerosis

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 102 participants
Very low

PUFA vs monounsaturated fatty acid (MUFA)

Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis

Polyunsaturated fatty acid (PUFA) showed no clear difference in global impression of deterioration (investigator defined global… compared with monounsaturated fatty acid (MUFA) (low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 0.85 [0.71, 1.03]
4 studies · 542 participants
Low

PUFA vs monounsaturated fatty acid (MUFA)

MRI activity ‐ not measured · people with multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PUFA vs monounsaturated fatty acid (MUFA)

SAEs · people with multiple sclerosis

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Omega‐3 vs omega‐6

Relapse · people with multiple sclerosis

Omega‐3 showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with omega‐6 (low certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 1.02 [0.62, 1.66]
2 studies · 129 participants
Low

Omega‐3 vs omega‐6

Change in validated disability scale ( · people with multiple sclerosis

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 166 participants
Low

Omega‐3 vs omega‐6

Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis

Omega‐3 showed no clear difference in global impression of deterioration (investigator defined global… compared with omega‐6 (moderate certainty).

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
RR 0.99 [0.51, 1.91]
1 study · 86 participants
Moderate

Omega‐3 vs omega‐6

MRI activity(assessed by new gadolinium‐enhancing lesions) · people with multiple sclerosis

1 finding from 1 review

Dietary interventions for multiple sclerosis‐related outcomes 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Moderate

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) vs placebo (3 tablets/4 times a day

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 4.23 [0.84, 21.38]
2 studies · 157 participants
Moderate

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 0.51 [0.34, 0.76]
2 studies · 93 participants
Moderate